Progression free survival (PFS) as a surrogate endpoint for overall survival (OS) in first-line advanced ovarian cancer (AOC) therapy: A Gynecologic Cancer InterGroup individual (GCIG) patient-level (IPD) analysis of multiple randomized trials
| العنوان: | Progression free survival (PFS) as a surrogate endpoint for overall survival (OS) in first-line advanced ovarian cancer (AOC) therapy: A Gynecologic Cancer InterGroup individual (GCIG) patient-level (IPD) analysis of multiple randomized trials |
|---|---|
| المؤلفون: | Liz-Anne Lewsley, Rosalind Glasspool, Tatsuo Kagimura, Gennaro Daniele, Anna V. Tinker, Stephen Welch, Ingrid A. Boere, Andrea Harkin, Gerasimos Aravantinos, Karamouza Eleni, Adrian Cook, Xavier Paoletti, Nozomu Yanaihara, Sandro Pignata, Petronella B. Ottevanger, Gunnar B. Kristensen, Robert Fruscio, Eric Pujade-Lauraine, Anna K.L. Reyners |
| المصدر: | Journal of Clinical Oncology. 36:5576-5576 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, Advanced ovarian cancer, Surrogate endpoint, business.industry, First line, Gold standard (test), law.invention, Clinical trial, Randomized controlled trial, law, Internal medicine, Gynecologic cancer, Medicine, Progression-free survival, business |
| الوصف: | 5576Background: OS is considered the gold standard endpoint for controlled clinical trials but it requires extended follow-up (median OS > 40 months for first line therapy) and large sample sizes. ... |
| تدمد: | 1527-7755 0732-183X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::64027215422dcf67db8b09d47aa36b73Test https://doi.org/10.1200/jco.2018.36.15_suppl.5576Test |
| رقم الانضمام: | edsair.doi...........64027215422dcf67db8b09d47aa36b73 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15277755 0732183X |
|---|